Global status of biosimilars and prospects in Asia

10^th International Conference and Exhibition on Biologics and Biosimilars

October 16-17, 2017 | San Francisco, USA

Md. Abu Zafor Sadek

University of Dhaka, Bangladesh

Scientific Tracks Abstracts: J Bioanal Biomed

Abstract :

Almost one decade back the first biosimilars was launched in Europe. Now they have 15 biosimilars and all are well accepted since high price branded biologics were tough to reach by many patients. Recently biosimilars has been endorsed everywhere in the world starting from developing to developed countries. United States Food and Drug Administration (USFDA) approved the first biosimilars in 2015 and currently they have 03 biosimilars which are playing pivotal role in price cutting of branded biologics. They also have many biosimilars to be launched shortly. Australia, Canada, Africa and Asia are also aggressive with biosimilars specially India, Korea, China made remarkable effort in biosimilars. However, considering the changes in disease pattern, increasing use of biological drugs, huge number of population, rising health awareness, recent economic growth, success history of some biologic companies, dependence on generic items, price sensitivity, relax regulation, growing health budget, very low production cost and other relevant factors, Asia is an important hub for biosimilars. Therefore, this study found out the prospects of biosimilars in Asia..

Biography :

Md. Abu Zafor Sadek has been serving as a Senior Additional Manager at Renata Limited, one of the top tier pharmaceutical companies of Bangladesh. Being graduated in Pharmacy from Khulna University, he started his career at Orion Pharmaceuticals Limited as Product Executive. Thereafter, he completed his MBA in International Business from Dhaka University. He has more than 10 years career in pharmaceutical management with excellent track record. His area of interests includes launching time demanded new products, brand management, strategy formulation, business opportunity identification, international business, training, presentation skills etc. In addition to his regular job, he is perusing for Doctor of Business Administration (DBA) Degree on growth potential of biosimilars products in Bangladesh from Institute of Business Administration (IBA), Dhaka University, and the leading business school of the country. He has four publications in different local and international journals. He has presented biosimilars and other topics at different conferences around the world including 5th European Biosimilars Congress, Valencia, Spain and 2nd Biosimilars Asia-Pacific Summit, Singapore. He is also involved in writing health column for the leading Bangladeshi newspapers